|Dr. Douglas M. Fambrough III||Co-Founder, CEO, Pres & Director||937.43k||1.8M||1969|
|Dr. Bob D. Brown||Exec. VP of R&D and Chief Scientific Officer||671.96k||564.75k||1965|
|Dr. Ralf H. Rosskamp||Consultant||707.13k||395.56k||1953|
|Mr. Robert D. Ciappenelli M.B.A.||Chief Commercial Officer||339.51k||N/A||1967|
|Dr. Mark Behlke||Co-Founder & Member of Scientific Advisory Board||N/A||N/A||N/A|
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiometabolic diseases. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; and a program for an undisclosed rare liver disease. The company's development programs also comprise DCR-A1AT programs; and a program for the treatment of neurodegeneration and pain. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, Roche, Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was founded in 2006 and is headquartered in Lexington, Massachusetts.
Dicerna Pharmaceuticals, Inc.’s ISS Governance QualityScore as of December 9, 2019 is 3. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 1; Compensation: 8.